Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. The Company’s operations and research and development activities are based in Israel.

Innocan Pharma’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) the research and development of CBD loaded exosomes (“CLX”); (ii) the research and development of the use of CBD loaded liposomes; and (iii) the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products.

Innocan Pharma is led by a multi-disciplinary management and R&D team, headed by:Iris Bincovich, an experienced healthcare Executive, Ron Mayron, former CEO of Teva Israel, one of the largest generic pharmaceutical companies in the world. Yoram Drucker Founder of two Nasdaq traded companies – Pluristem & Brainstorm, working with stem cells, Nir Avram, former member of the pharma innovation team at Perrigo, Prof. Hezy Barenholz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem and Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology, Head of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University.